Importantly, ACE2 activity is significantly reduced in the frontal cortex and hypothalamus of OXYS AD rats and in the mid-frontal cortex of AD patients, and this is associated with increased parenchymal Aβ and Tau levels [25, 26]. The gene discussed is MAPT; the disease is Alzheimer disease.